How effective is Phesgo

The short version: Phesgo is a fixed-dose combination of two HER2-blocking antibodies (pertuzumab and trastuzumab) given as a single shot under the skin instead of separate IV infusions. The evidence that the combination works comes from trials where both antibodies were given separately by IV, not from trials of the subcutaneous combo itself.

The key trial for the dual-antibody strategy is CLEOPATRA, a randomized, double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer getting first-line treatment [3]. Adding pertuzumab to trastuzumab plus docetaxel extended median progression-free survival from 12.4 months to 18.5 months [3]. That is a real clinical endpoint, and the trial was large enough to trust the direction of the effect. The same combination in the neoadjuvant setting (NEOSPHERE, 417 patients) raised the pathological complete response rate from 29% to 45.8% [3]. A 2015 meta-analysis of 22 randomized trials covering 19,138 patients found that HER2 blockade did not significantly increase treatment-related mortality compared to controls, with rates around 0.3% in both arms [1].

What the evidence does not tell you is whether the subcutaneous formulation (Phesgo) works as well as the IV version in the real world. The retrieved studies all used IV trastuzumab and IV pertuzumab given separately. Phesgo was approved on a pharmacokinetic equivalence study, not a clinical outcome trial. That means the approval assumes the body absorbs and distributes the drugs the same way when injected under the skin. That assumption may hold, but it has not been tested against a hard endpoint like survival in a randomized trial.

The safety profile of the dual-antibody combination is not trivial. In CLEOPATRA, the pertuzumab arm had higher rates of neutropenia, diarrhea, and rash [3]. In the KRISTINE trial (444 patients, neoadjuvant), the docetaxel-carboplatin-trastuzumab-pertuzumab arm had 141 grade 3-4 adverse events and 63 serious events, compared to 29 and 11 in the trastuzumab-emtansine-pertuzumab arm [4]. Cardiac toxicity was not significantly increased in the meta-analysis, but individual patients did experience LVEF drops [2]. The DESTINY-Breast09 trial (2025, 1,160 patients) tested a newer antibody-drug conjugate (trastuzumab deruxtecan) plus pertuzumab and found an interstitial lung disease rate of 12.1%, with 2 deaths [5]. That is a different drug, but it shows that combining HER2-targeted agents carries real pulmonary risk.

My call: Phesgo is likely as effective as the IV dual-antibody combination for HER2-positive breast cancer, but the evidence for that claim is extrapolated from IV trials, not proven in the subcutaneous formulation itself. The benefit is real for metastatic disease (about 6 months extra progression-free survival) and for neoadjuvant treatment (higher pathological complete response). The harms are also real: chemotherapy-grade side effects, cardiac monitoring required, and a small but nonzero risk of serious adverse events. Confidence: moderate for the drug class, low for the subcutaneous formulation specifically.